AML Clinical Roadmap 2024 – AML Clinical Roadmap 2024

You need to register to watch content!

MD Education

FREE

JANUARY/2024

Role of MRD in transplant decision making in AML – Roland Walter – University of Washington, USA

Updates and future directions for post-transplant maintenance – Charlie Craddock – Queen Elizabeth Hospital, UK

FEBRUARY/2024

Who should we transplant in AML and how: moving towards greater precision in transplant decision making – Alessandro Rambaldi – University of Milan, IT

CPX351 in Frontline AML: Current status and Future directions: Real world CPX analysis – Christina Rautenburg – University Hospital Essen, DE

MARCH/2024

Novel strategies with the potential to improve outcomes in patients treated with HMA-venetoclax: up-front triplets versus sequential add-on approaches Naval Daver – MD Anderson Cancer Center, USA

Updates on current status of Menin inhibitor single agent: Efficacy, safety, biomarkers of response and mechanisms of resistance – Ghayas Issa – MD Anderson Cancer Center, USA

APRIL/2024

Novel immunotherapeutic approaches in AML: Bispecific Antibodies: MOA and clinical development – Marion Subklewe – Gene Center, USA

Novel immunotherapeutic approaches in AML: CART therapies in AML: current status and future prospects – Saar Gill – University of Pennsylvania, USA

MAY/2024

TP53 targeted therapies in AML: Current status and emerging therapies – Paresh Vyas – University of Oxford, UK

IDH-1 and IDH-2 inhibitors: Targeted therapies for unfit patience in AML moving from R/R to Frontline use – Courtney Di Nardo – MD Anderson Cancer Center, USA

JUNE/2024

Optimizing outcomes in older adults treated with venetoclax based therapies Mechanisms of resistance and potential combinations – Andrew Wei- Monash University, AU

Updates on ELN2022 and integrating genomic information into decision making in AML – Hartmut Doehner – University Hospital of Ulm, DE

JULY/2024

nnovative treatment strategies in fit and unfit adults with Flt3+ AML – Jessica Altman – University of Pennsylvania, USA

NPM1 directed therapies: Optimal application in frontline or MRD+ setting – Richard Dillon – King’s College London, UK

AUGUST/2024

Novel relapse strategies in relapsed AML – Christoph Rollig – University Hospital Carl Gustav Carus, DE

Familial AML – George Vassiliou – University of Cambridge, UK

SEPTEMBER/2024

Antibody based therapies in AML- Mylotarg and beyond – Amir Fathi – Dana-Farber /Harvard Cancer Center, USA

Improving outcomes in adults with APML – Steve Knapper – Cardiff University, UK

OCTOBER/2024

Molecular prognostication and genomics of newly diagnosed AML – Marina Konopleva – Montefiore Einstein Cancer Center, USA

Role of MRD in optimizing outcomes in older adults treated with HMA/VEN regimens-is it ever possible to safely stop therapy – Daniel Pollyea – University of Colorado, USA

NOVEMBER/2024

Integrating MRD into management of fit adults with AML: who, when and how? – Sylvie Freeman – University of Birmingham, UK

The role of venetoclax in improving outcomes in fit adults with newly diagnosed and relapsed AML – Farhad Ravandi – MD Anderson Cancer Center, USA

DECEMBER/2024

Maintenance based approaches and future of maintenance therapy in AML approaches to maintenance in AML – GaiI Roboz – Weill Medical College of Cornell University, USA

Immune based therapies in AML and MDS: Future directions and prospects – Amer Zeidan – Yale University, UK

You need to register to watch content!

MD Education

JANUARY/2024

Role of MRD in transplant decision making in AML – Roland Walter – University of Washington, USA

Updates and future directions for post-transplant maintenance – Charlie Craddock – Queen Elizabeth Hospital, UK

FEBRUARY/2024

Who should we transplant in AML and how: moving towards greater precision in transplant decision making – Alessandro Rambaldi – University of Milan, IT

CPX351 in Frontline AML: Current status and Future directions: Real world CPX analysis – Christina Rautenburg – University Hospital Essen, DE

MARCH/2024

Novel strategies with the potential to improve outcomes in patients treated with HMA-venetoclax: up-front triplets versus sequential add-on approaches Naval Daver – MD Anderson Cancer Center, USA

Updates on current status of Menin inhibitor single agent: Efficacy, safety, biomarkers of response and mechanisms of resistance – Ghayas Issa – MD Anderson Cancer Center, USA

APRIL/2024

Novel immunotherapeutic approaches in AML: Bispecific Antibodies: MOA and clinical development – Marion Subklewe – Gene Center, USA

Novel immunotherapeutic approaches in AML: CART therapies in AML: current status and future prospects – Saar Gill – University of Pennsylvania, USA

MAY/2024

TP53 targeted therapies in AML: Current status and emerging therapies – Paresh Vyas – University of Oxford, UK

IDH-1 and IDH-2 inhibitors: Targeted therapies for unfit patience in AML moving from R/R to Frontline use – Courtney Di Nardo – MD Anderson Cancer Center, USA

JUNE/2024

Optimizing outcomes in older adults treated with venetoclax based therapies Mechanisms of resistance and potential combinations – Andrew Wei- Monash University, AU

Updates on ELN2022 and integrating genomic information into decision making in AML – Hartmut Doehner – University Hospital of Ulm, DE

JULY/2024

nnovative treatment strategies in fit and unfit adults with Flt3+ AML – Jessica Altman – University of Pennsylvania, USA

NPM1 directed therapies: Optimal application in frontline or MRD+ setting – Richard Dillon – King’s College London, UK

AUGUST/2024

Novel relapse strategies in relapsed AML – Christoph Rollig – University Hospital Carl Gustav Carus, DE

Familial AML – George Vassiliou – University of Cambridge, UK

SEPTEMBER/2024

Antibody based therapies in AML- Mylotarg and beyond – Amir Fathi – Dana-Farber /Harvard Cancer Center, USA

Improving outcomes in adults with APML – Steve Knapper – Cardiff University, UK

OCTOBER/2024

Molecular prognostication and genomics of newly diagnosed AML – Marina Konopleva – Montefiore Einstein Cancer Center, USA

Role of MRD in optimizing outcomes in older adults treated with HMA/VEN regimens-is it ever possible to safely stop therapy – Daniel Pollyea – University of Colorado, USA

NOVEMBER/2024

Integrating MRD into management of fit adults with AML: who, when and how? – Sylvie Freeman – University of Birmingham, UK

The role of venetoclax in improving outcomes in fit adults with newly diagnosed and relapsed AML – Farhad Ravandi – MD Anderson Cancer Center, USA

DECEMBER/2024

Maintenance based approaches and future of maintenance therapy in AML approaches to maintenance in AML – GaiI Roboz – Weill Medical College of Cornell University, USA

Immune based therapies in AML and MDS: Future directions and prospects – Amer Zeidan – Yale University, UK

FACULTY REVIEW

FACULTY GROUP REVIEW AT THE END OF THE 12 MONTHS TO REFLECT ON KEY DEVELOPMENTS

If you would like additional information or have any questions, please email:

office@md-education.com

ORGANISED BY:

UK Office

USA Office